Lifeboat Foundation

Tesla’s recent move to open its Supercharger network to other automakers will enable the automaker to get access to some of the $7.5 billion in EV charging infrastructure funding as part of the new US infrastructure bill.

For years now, Tesla has been talking about opening up the Supercharger network to electric vehicles from other manufacturers.

Last month, CEO Elon Musk finally confirmed that Tesla plans to open Superchargers to other automakers later this year.

The sophisticated new research station will allow for better science on the icy continent.

One of the biggest factors affecting consumer adoption of electric vehicles (EVs) is the amount of time required to recharge the vehicles—usually powered by lithium-ion batteries. It can take up to a few hours or overnight to fully recharge EVs, depending on the charging method and amount of charge remaining in the battery. This forces drivers to either limit travel away from their home chargers or to locate and wait at public charging stations during longer trips.

Why does it take so long to fully charge a battery, even those used to power smaller devices, such as mobile phones and laptops? The primary reason is that devices and their chargers are designed so the rechargeable lithium-ion batteries charge only at slower, controlled rates. This is a safety feature to help prevent fires, and even explosions, due to tiny, rigid tree-like structures, called dendrites, that can grow inside a lithium battery during fast charging and induce short-circuits inside the battery.

To address the need for a more practical lithium-ion battery, researchers from the University of California San Diego (UC San Diego) worked with scientists at Oak Ridge National Laboratory (ORNL) to conduct neutron scattering experiments on a new type of material that could be used to make safer, faster-charging batteries. The researchers produced samples of lithium vanadium oxide (Li3V2O5), a “disordered rock salt” similar to table salt but with a certain degree of randomness in the arrangement of its atoms. The samples were placed in a powerful neutron beam that enabled observing the activity of ions inside the material after a voltage was applied.

Its powers may not rival Wolverine’s, but a regenerative implant engineered by researchers at the University of Nebraska Medical Center and University of Nebraska–Lincoln could help repair bone-deep damage following physical trauma, surgery or osteoporosis.

The team has developed a biodegradable, nanofiber-based implant, or scaffold, whose design could better regenerate bone by effectively guiding the migration of recuperative cells to the injury site. When implanted in rats with bone defects, the cylindrical scaffold promoted the regeneration of bone that was denser, more voluminous and more like the surrounding tissue than that achieved by many other state-of-the-art designs.

The implant spurred regeneration even without the aid of externally sourced stem cells or so-called growth factors, which help promote healing but can also introduce regulatory complications and side effects that range from inflammation to unchecked tissue formation.

A new study detected coronavirus antibodies in 40 percent of deer tested this year. Here’s why that matters.

Although visible signs of aging are usually unmistakable, unraveling what triggers them has been quite a challenge. Researchers at Baylor College of Medicine and collaborating institutions have discovered that a cellular phenomenon called cryptic transcription, which had been previously described and linked to aging in yeasts and worms, is elevated in aging mammalian stem cells.

The team reports in the journal Nature Aging that cryptic transcription occurs because a cellular mechanism that keeps it in check falls apart as cells get old. The findings suggest that strategies that control cryptic transcription could have pro-longevity effects.

“In previous work, we showed that cryptic transcription in yeasts and worms is not only a marker of aging but also a cause,” said corresponding author Dr. Weiwei Dang, assistant professor of molecular and human genetics and the Huffington Center on Aging at Baylor. “Reducing the amount of this aberrant transcription in these organisms prolonged their lifespan.”

Capricor on April 3 said it was continuing to develop its exosome platform technology as a potential COVID-19 vaccine, even as it pursued compassionate use approval for CAP-1002 (See above). The company seeks to develop two candidates. The first is a virus-like particle (VLP) similar in structure to an exosome, and produced by the same process developed by Capricor in its studies of CAP-1002. The other is an exosome-mRNA vaccine formulation designed to elicit a protective, long-lasting immune response to SARS-CoV-2 by targeting all four structural proteins of the virus.

Candidates: Two vaccine candidates for the potential prevention of COVID-19.

Category: VAX

Continue reading “Capricor Therapeutics – Exosome-based vaccine program” »

A COVID-19 vaccine in a pill being developed by Vaxart and a nasal spray from Altimmune could offer convenience and maybe even superior immunity compared to injections.